6lcb: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of human Dishevelled1 PDZ domain with its inhibitor NPL3009== | ==Crystal structure of human Dishevelled1 PDZ domain with its inhibitor NPL3009== | ||
<StructureSection load='6lcb' size='340' side='right'caption='[[6lcb]]' scene=''> | <StructureSection load='6lcb' size='340' side='right'caption='[[6lcb]], [[Resolution|resolution]] 1.40Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LCB OCA]. For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>[[6lcb]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LCB OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LCB FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.4Å</td></tr> | ||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=E83:2-[[3-[(2E)-2-[1,3-bis(oxidanylidene)-1-phenyl-butan-2-ylidene]hydrazinyl]phenyl]sulfonylamino]benzoic+acid'>E83</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lcb FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lcb OCA], [https://pdbe.org/6lcb PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lcb RCSB], [https://www.ebi.ac.uk/pdbsum/6lcb PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lcb ProSAT]</span></td></tr> | |||
</table> | </table> | ||
== Disease == | |||
[https://www.uniprot.org/uniprot/DVL1_HUMAN DVL1_HUMAN] Autosomal dominant Robinow syndrome. The disease is caused by variants affecting the gene represented in this entry. | |||
== Function == | |||
[https://www.uniprot.org/uniprot/DVL1_HUMAN DVL1_HUMAN] Participates in Wnt signaling by binding to the cytoplasmic C-terminus of frizzled family members and transducing the Wnt signal to down-stream effectors. Plays a role both in canonical and non-canonical Wnt signaling. Plays a role in the signal transduction pathways mediated by multiple Wnt genes. Required for LEF1 activation upon WNT1 and WNT3A signaling. DVL1 and PAK1 form a ternary complex with MUSK which is important for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). | |||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Homo sapiens]] | |||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
[[Category: Hiroaki H]] | [[Category: Hiroaki H]] | ||
Latest revision as of 13:56, 22 November 2023
Crystal structure of human Dishevelled1 PDZ domain with its inhibitor NPL3009Crystal structure of human Dishevelled1 PDZ domain with its inhibitor NPL3009
Structural highlights
DiseaseDVL1_HUMAN Autosomal dominant Robinow syndrome. The disease is caused by variants affecting the gene represented in this entry. FunctionDVL1_HUMAN Participates in Wnt signaling by binding to the cytoplasmic C-terminus of frizzled family members and transducing the Wnt signal to down-stream effectors. Plays a role both in canonical and non-canonical Wnt signaling. Plays a role in the signal transduction pathways mediated by multiple Wnt genes. Required for LEF1 activation upon WNT1 and WNT3A signaling. DVL1 and PAK1 form a ternary complex with MUSK which is important for MUSK-dependent regulation of AChR clustering during the formation of the neuromuscular junction (NMJ). |
| ||||||||||||||||||